FDA Vulnerable To Meddling In Climate Of Distrust – Commish Hamburg
This article was originally published in The Rose Sheet
An atmosphere of distrust in government makes FDA vulnerable to congressional meddling, Commissioner Margaret Hamburg suggested in a July 25 presentation to consumer group Public Citizen.
You may also be interested in...
FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg
FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.
House Cuts WIC Funding In Appropriations Bill
The House passes a fiscal 2012 appropriations bill with significant cuts to a program that provides infant formula for low-income women.
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.